View Older Stories View More Recent Stories
-
Bristol-Myers Squibb (BMY) call put ratio 1.6 calls to 1 put into quarter results
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $55 at Cantor Fitzgerald
-
Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for Opdivo plus Yervoy as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
-
Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
-
Cantor Fitzgerald provides update on Biotechnology stocks
-
Bernstein Weighs in on US Biopharma Sector in 2025; Highlights LLY as Top-pick
-
Bristol-Myers Squibb (BMY) and ArsenalBio Achieve Milestone for AB-4000 Series
-
Bristol Myers Squibb Named to Dow Jones Sustainability Index North America for Second Consecutive Year
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $65 at Truist Securities, Expects Launches to Drive Momentum
-
TD Cowen on Pharma: '10 Events in 2025 That Could Change Practice, Alter Companies, Move Stocks'
-
TD Cowen on Trump Tariffs and Other Risks: 'Where Does Pharma Stand?'
-
Bristol-Myers Squibb (BMY) Announces Positive Topline Results from Two Pivotal Phase 3 Trials of Sotyktu
-
Bristol-Myers Squibb (BMY) Receives EU Approval for Opdivo plus Yervoy for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Col
-
JPMorgan Adds Bristol-Myers Squibb Co. (BMY) to Aanalyst Focus List
-
Bristol-Myers Squibb (BMY) calls more active than puts on flat option IV
-
Jefferies Upgrades Bristol-Myers Squibb Co. (BMY) to Buy
-
Jefferies Upgrades Bristol-Myers Squibb Co. (BMY) to Buy, 'Why we're upgrading'
-
Bristol-Myers Squibb (BMY) Files Mixed Shelf
-
Bristol-Myers Squibb (BMY) Raises Quarterly Dividend 3.3% to $0.62; 4.4% Yield
-
Truist: 'Potential Impact of Trump's Nominees on Biopharma'
-
CFRA Downgrades BMY (BMY) to Hold Strictly on Valuation, 'we think shares are fairly valued', 'continue to see BMY as better positioned for growth'
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $62 at Bernstein SocGen Group
-
Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for Opdivo plus Yervoy
-
Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for Repotrectinib
-
Stocks expected to have increasing option volume: AMAT ASTS BILI OKLO JD BABA WMT LOW BMY LLY AMGN GSK MRNA MRK AZN GILD NVO PCVX UNH CVX AET CI HUM WBA CELG
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $61 at BMO Capital
-
Leerink Partners Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform
-
Bristol-Myers Squibb (BMY) Climbs 10% After AbbVie's Results for Emraclidine in Schizophrenia Did Not Meet their Primary Endpoint
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $55 at Leerink Partners
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at BMO Capital
-
Bristol-Myers Squibb (BMY) Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY
-
Bristol-Myers Squibb (BMY) Tops Q3 EPS by 30c, provides guidance
-
Bristol-Myers Squibb (BMY) call put ratio 1.6 calls to 1 put into quarter results
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $59 at TD Cowen
-
Bristol-Myers Squibb (BMY) Reports FDA Approval of Perioperative Treatment of Neoadjuvant Opdivo and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable NSCLC
-
Prime Medicine (PRME) Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
-
Bristol-Myers Squibb (BMY) Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
-
Morgan Stanley on Zai Lab (ZLAB) Post BMY (BMY) Approval: 'We believe it should bode moderately positively for ZLAB shares'
-
JPMorgan Positive on Bristol-Myers Squibb Co. (BMY): 'We Expect Strong Uptake Mid2025 and Beyond'
-
Bristol-Myers Squibb (BMY) Climbs 5% After Schizophrenia Drug Cleared by FDA
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $53 at BMO Capital
-
PureTech Health Plc (PRTC) -Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
-
Goldman Sachs Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)
-
Bristol-Myers Squibb (BMY) Announces FDA Approval of COBENFY
-
BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)
-
Bristol-Myers Squibb (BMY) Reports New Long-Term Zeposia Data Showing Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
-
Immatics (IMTX) Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule
-
Goldman Sachs Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $51 at Jefferies
-
Bristol-Myers Squibb (BMY) Announces FDA sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
